IceCure Medical Ltd. participated in the Radiological Society of North America's (RSNA) Annual Meeting, held from November 30 to December 4, 2025, in Chicago, Illinois. At this prestigious event, four independent studies featuring IceCure's ProSense® cryoablation technology for breast cancer treatment were presented. The studies, conducted by ProSense® users, highlighted the effectiveness and growing adoption of the company's minimally-invasive cryoablation system as an alternative to surgical tumor removal. The event attracted around 50,000 attendees from 160 countries, providing a global platform for showcasing advancements in radiology and cancer care.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: IO43376) on December 10, 2025, and is solely responsible for the information contained therein.
Comments